Infinity Pharmaceuticals Financial Ratios

Infinity Pharmaceuticals Inc -- USA Stock  

USD 2.1  0.18  7.89%

We strongly advise you to harness analysis of Infinity Pharmaceuticals fundamentals to see if markets are presently mispricing the organization. We found thirty-one available reported financial drivers for Infinity Pharmaceuticals which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Infinity Pharmaceuticals fundamentals including its Debt to Equity, Beta and the relationship between EBITDA and Short Ratio . Please also validate Infinity Pharmaceuticals Price to Earning to confirm the company can sustain itself down the road.Use Infinity Pharmaceuticals to protect against small markets fluctuations. The stock experiences very speculative upward sentiment.. Check odds of Infinity Pharmaceuticals to be traded at $1.995 in 30 days

Infinity Pharmaceuticals Valuation Over Time

Enterprise Value

Infinity Pharmaceuticals Company Summary

Infinity Pharmaceuticals competes with NantKwest, Del Mar, Dimension Therapeutics, VBI Vaccines, and Vascular Biogenic. Its lead product candidate includes IPI145 an oral inhibitor of the delta and gamma isoforms of phosphoinositide3kinase for the treatment of hematologic malignancies. Infinity Pharmaceuticals Inc is developing DYNAMO which is in Phase II study to evaluate the safety and efficacy of IPI145 dosed at 25 mg CONTEMPO that is in the Phase IbII study of IPI145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma BRAVURA which is in Phase III study to evaluate the safety and efficacy of IPI145 plus rituximab and bendamustine and FRESCO that is in Phase II study to evaluate the safety and efficacy of IPI145 plus rituximab. It is also developing DYNAMOR which is in Phase III randomized study to evaluate IPI145 dosed at 25 mg in combination with rituximab a monoclonal antibody treatment DUO that is in randomized Phase III monotherapy study evaluating IPI145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia and SYNCHRONY which is in the Phase Ib study of IPI145 in combination with obinutuzumab in CLL patients. In addition Infinity Pharmaceuticals Inc is conducting a Phase IbII trial of IPI145 in combination with venetoclax a Bcell lymphoma 2 inhibitor and developing IPI549 that is in Phase I study for patients with various solid tumors including melanoma and nonsmall cell lung cancer. Infinity Pharmaceuticals Inc has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI145 in oncology and development and license agreement with Intellikine Inc. to discover develop and commercialize pharmaceutical solutions targeting the delta andor gamma isoforms of PI3K. Infinity Pharmaceuticals Inc. is headquartered in Cambridge Massachusetts.

Infinity Pharmaceuticals Price to Earning vs Current Ratio

Infinity Pharmaceuticals Inc is rated third overall in price to earning category among related companies. It is rated second overall in current ratio category among related companies .

Infinity Pharmaceuticals Fundamentals

 Better Than Average     
 Worse Than Average Compare Infinity Pharmaceuticals to competition
FundamentalsInfinity PharmaceuticalsPeer Average
Return On Equity(78.61) % (15.17) %
Return On Asset(26.58) % (15.64) %
Current Valuation(8.41 M)152.14 B
Shares Outstanding50.69 M1.43 B
Shares Owned by Insiders2.57 % 6.91 %
Shares Owned by Institutions72.41 % 18.37 %
Number of Shares Shorted1.39 M3.24 M
Price to Earning(2.12) times40.69 times
Price to Book2.53 times14.44 times
Gross Profit18.72 M21.75 B
EBITDA(55.73 M)1.41 B
Net Income(69.61 M)517.71 M
Cash and Equivalents66.2 M3.89 B
Cash per Share1.31 times5.17 times
Debt to Equity0.23 % 0.72 %
Current Ratio6.29 times3.3 times
Book Value Per Share1.17 times13.64 times
Cash Flow from Operations(82.94 M)1.25 B
Short Ratio4 times2.09 times
Earnings Per Share(1.39) times2.3 times
Price to Earnings To Growth(0.05) times1.22 times
Number of Employees4810.67 K
Market Capitalization149.53 M29.78 B
Total Asset288.82 M126.86 B
Retained Earnings(595.59 M)38.24 B
Working Capital184.64 M3.58 B
Current Asset254.7 M36.8 B
Current Liabilities70.06 M33.34 B
Z Score-2.8708.73
< 63% 

Chance of Financial Distress

Infinity Pharmaceuticals Inc has more than 63 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info


Infinity Pharmaceuticals Growth Changes

EPS Diluted Growth

EPS Growth

NCFO Growth


Compare Infinity Pharmaceuticals To Peers
Adelene Perkins Chairman of The Board, CEO and Pres, MBA
Joseph Pearlberg Vice President - Clinical Development, Ph.D
More Executives

Opportunity Range

October 21, 2017 Opportunity Range